VCYTMEDIUM SIGNALOPPORTUNITY10-K

Veracyte is strategically pivoting toward expanded cancer testing capabilities with the launch of TrueMRD for minimal residual disease detection and Prosigna as a U.S. laboratory-developed test, while demonstrating strong operational execution.

The company is broadening its oncology testing portfolio beyond its core Decipher and Afirma franchises, positioning to capture more of the cancer care continuum through MRD testing. The strategic focus on expanding existing test penetration while launching new capabilities suggests a disciplined approach to growth in the precision medicine market.

Comparing 2026-02-26 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

Veracyte delivered solid growth with revenue expanding 16% to $517.1M and gross profit increasing 21.6% to $362.5M, indicating improving operational leverage. Operating cash flow grew substantially to $136.3M, reflecting strong underlying business performance and cash generation. The balance sheet strengthened notably with cash rising 52% to $362.6M while total liabilities declined 22%, providing significant financial flexibility for continued investment in growth initiatives.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+81.5%
$75.1M→$136.3M

Operating cash flow surged 81.5% — exceptional cash generation, highest quality earnings signal.

Interest Expense
P&L
-66.2%
$677K→$229K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
+51.7%
$239.1M→$362.6M

Cash position surged 51.7% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+31.2%
$372.3M→$488.4M

Current assets grew 31.2% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
-23.8%
$78.6M→$59.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-22.3%
$124.1M→$96.4M

Liabilities reduced 22.3% — deleveraging improves balance sheet strength and financial flexibility.

Gross Profit
P&L
+21.6%
$298.1M→$362.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+16%
$445.8M→$517.1M

Revenue growing 16% — solid top-line momentum, watch margins for quality of growth.

Stockholders Equity
Balance Sheet
+11.4%
$1.2B→$1.3B

Equity base grew 11.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-28
ADDED
"Veracyte," "Afirma," "Percepta," "Envisia," "Prosigna," "Lymphmark," "Decipher," "GRID," "C2i", "C2i Genomics" and the Veracyte logo are registered trademarks, and "TrueMRD" is a pending trademark application, of Veracyte, Inc.
Our international distribution of IVDs is currently focused on our Prosigna test and, in the future, we intend to offer Decipher Prostate as an IVD.
In the near-term, we are focused on continuing to expand Decipher Prostate's penetration and leadership position while also sustaining strong growth for Afirma.
In particular, we are prioritizing the following growth drivers: the launch of TrueMRD, our minimal residual disease, or MRD, platform to expand our reach further across the cancer care continuum and the launch of Prosigna as an LDT for the U.S.
market to be able to serve more patients in the United States who face a breast cancer diagnosis.
+7 more — sign up free →
REMOVED
When used in this report, all references to "Veracyte," the "company," "we," "our" and "us" refer to Veracyte, Inc., together with its consolidated subsidiaries, unless otherwise noted.
Immunoscore is the registered trademark of Institut National de la Sant et de la Recherche M dicale, or Inserm, in the United States and selected countries and used by Veracyte under license.
Additionally, our Percepta Nasal Swab test is currently being run in our CLIA labs in support of clinical studies.
Our international distribution of IVDs is currently limited to our Prosigna test, however, in the future, we intend to offer Decipher Prostate and Percepta Nasal Swab as IVDs.
In the near-term, we are focused on continuing to expand Decipher Prostate's market size, penetration, and leadership position while also sustaining strong growth for Afirma.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
ABTHIGHAbbott announced a major strategic acquisition of Exact Sciences Corporation to ...
2026-02-20
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →